Scott Goldsmith, M.D.

(877) 460-4673
Scott Goldsmith, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Multiple Myeloma
Research Area
  • Hematology and Hematopoietic Cell Transplantation
  • Multiple Myeloma
Academic Appointments
  • Assistant Professor, Division of Multiple Myeloma, Department of Hematology & Hematopoietic Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Myeloma and Multiple Myeloma

I am reminded each day how lucky I am to be in this profession. — Scott Goldsmith, M.D.

Dr. Goldsmith specializes in the treatment of multiple myeloma, which is also the focus of his prolific research.

“I am passionate about bringing new and innovative treatments to patients with multiple myeloma and other hematologic malignancies through translational research and clinical trials,” he said.

Dr. Goldsmith entered medicine because he remembers how well he was treated when he was a patient in his teen years. “I felt firsthand the profound, lasting impact that healthcare professionals can have on an individual,” he recalled. He credits that experience with informing the way he practices medicine today: “To listen carefully, communicate clearly, and understand who my patients are as people.”

A Florida native, Dr. Goldsmith graduated with honors from the University of Florida — Gainesville, FL, then earned his medical degree at UF’s College of Medicine and continued his training at Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO.

Dr. Goldsmith takes pride in the relationships he forms with his patients, and he is intent on making an impact “at an individual, institutional, and global level” in finding better treatments for multiple myeloma. He feels City of Hope, with its bench-to-bedside philosophy, is the ideal place to be.

“I feel really fortunate to become a part of this institution and contribute to these missions.”

Location

Education & Experience

Degrees

  • 2013, Doctor of Medicine, University of Florida, Gainesville, FL

Fellowship

  • 2018–2021, Clinical Fellow, Hematology and Medical Oncology, Barnes-Jewish Hospital, Washington University, St. Louis, MO

Residency

  • 2016–2017, Chief Residency, Internal Medicine, Barnes-Jewish Hospital, Washington University, St. Louis, MO
  • 2013–2016, Residency, Internal Medicine, Barnes-Jewish Hospital, Washington University, St. Louis, MO

Professional Experience

  • 2021–present, Assistant Professor, Department of Hematology & Hematopoietic Transplantation, City of Hope, Duarte, CA
  • 2017–2018, Bone Marrow Transplant Hospitalist, Barnes-Jewish Hospital, Washington University, St. Louis, MO
  • 2016–2018, Instructor of Medicine, Department of Internal Medicine, Barnes-Jewish Hospital, Washington University, St. Louis, MO

Awards & Memberships

Awards

  • 2023 Steven Gordon & Briskin Family Innovation Grant
  • 2022 Hematological Malignancies (HM) Program Project Award
  • 2020, Transplantation and Cellular Therapies Conference Abstract Travel Award
  • 2015, Mentors in Medicine Research Grant
  • 2021, Hanna Khoury Award for Outstanding Graduating Hematology/Oncology Fellow

Publications

Peer-Reviewed Manuscripts

  • Goldsmith, S., Harris, M., Scherer, K., Al-Quran, S., & Vorhis, E. Sarcoidosis manifesting as a pseudotumorous renal mass. Sarcoidosis manifesting as a pseudotumorous renal mass. J Radiol Case Rep. 2013 May 1;7(5):23-34. doi: 10.3941/jrcr.v7i5.1316. Print 2013 May. PubMed PMID: 23705054
  • Goldsmith, S.R., Slade, M., DiPersio, J.F., Westervelt, P., Lawrence, S.J., Uy, G.L., Abboud, C.N., Vij, R., Schroeder, M.A., Fehniger, T.A., Dubberke, E.R., Trinkaus, K., & Romee, R. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. 2016 Nov;101(11):e465-e468. PubMed PMID: 27443287.
  • Slade, M., Goldsmith, S., Romee, R., DiPersio, J.F., Dubberke, E.R., Westervelt, P., Uy, G.L.,  & Lawrence, S.J. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2016 Nov 7. doi: 10.1111/tid.12629. [Epub ahead of print] PubMed PMID: 28030755.
  • Goldsmith, S.R., Slade, M., DiPersio, J.F., Westervelt, P., Schroeder, M.A., Gao, F., & Romee, R. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant. 2017 Dec;52(12):1623-1628. doi: 10.1038/bmt.2017.193. Epub 2017 Oct. PubMed PMID: 29035393
  • Goldsmith, S.R., Fiala, M.A., Dukeman, J., Ghobadi, A., Stockerl-Goldstein, K., Schroeder, M.A., Tomasson, M., Wildes, T.M., & Vij, R. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. Clin Lymphoma Myeloma Leuk. 2019 Jan 19. pii: S2152-2650(18)31524-6. doi: 10.1016/j.clml.2019.01.003. [Epub ahead of print] PubMed PMID: 30792096
  • Goldsmith, S.R., Fiala, M.A., O'Neal, J., Souroullas, G.P., Toama, W., Vij, R., & Schroeder, M.A. EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. Clin Lymphoma Myeloma Leuk. 2019 Aug 30. pii: S2152-2650(19)31380-1. doi: 10.1016/j.clml.2019.08.010. [Epub ahead of print] PubMed PMID: 31551170.
  • Fiala, M.A., Vosuri, V., Goldsmith, S., Schroeder, M.A., Ghobadi, A., Wildes, T.M., Stockerl-Goldstein, K.E., & Vij, R. Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant. 2019 Aug 28. doi: 10.1038/s41409-019-0663-5. [Epub ahead of print] PubMed PMID: 31462683
  • Goldsmith, S.R., Saif Ur Rehman, S., Shirai, C.L., Vij, K., & DiPersio, J.F. Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Blood Adv. 2019 Dec 10;3(23):4131-4135.
  • Goldsmith, S.R., Fiala, M.A., Wang, B., Schroeder, M.A., Wildes, T.M., Ghobadi, A., Stockerl-Goldstein, K., & Vij, R. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Ann Hematol. 2020 Mar 4. doi: 10.1007/s00277-020-03970-2. [Epub ahead of print]
  • Fiala, M.A., King, J., Feinberg, D., Goldsmith, S.R., Schroeder, M.A., Ghobadi, A., Stockerl-Goldstein, K.E., Vij, R., & Wildes, T.M. Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. Bone Marrow Transplant. 2021 Apr 19. doi: 10.1038/s41409-021-01295-w. Epub ahead of print. PMID: 33875814.
  • Liu, R., Gao, Q., Foltz, S.M., Fowles, J.S., Yao, L., Wang, J.T., Cao, S., Sun, H., Wendl, M.C., Sethuraman, S., Weerasinghe, A., Rettig, M.P., Storrs, E.P., Yoon, C.J., Wyczalkowski, M.A., McMichael, J.F., Kohnen, D.R., King, J., Goldsmith, S.R., O'Neal, J., Fulton, R.S., Fronick, C.C., Ley, T.J., Jayasinghe, R.G., Fiala, M.A., Oh, S.T., DiPersio, J.F., Vij, R., & Ding, L. Co-evolution of tumor and immune cells during the progression of multiple myeloma. Nat Commun. 2021 May 7;12(1):2559. doi: 10.1038/s41467-021-22804-x. PMID: 33963182; PMCID: PMC8105337.
  • Goldsmith, S.R. & Vij, R. Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions. JCO Oncol Pract. 2021 Jul;17(7):415-418. doi: 10.1200/OP.21.00210. Epub 2021 Jun 10. PMID: 34110937.
  • Goldsmith, S.R., Abid, M.B., Auletta, J.J., Bashey, A., Beitinjaneh, A., Castillo, P., Chemaly, R.F., Chen, M., Ciurea, S., Dandoy, C.E., Díaz, M.Á., Fuchs, E., Ganguly, S., Kanakry, C.G., Kanakry, J.A., Kim, S., Komanduri, K.V., Krem, M.M., Lazarus, H.M., Liu, H., Ljungman, P., Masiarz, R., Mulroney, C., Nathan, S., Nishihori, T., Page, K.M., Perales, M.A., Taplitz, R., Romee, R., & Riches, M. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 Jun 10;137(23):3291-3305. doi: 10.1182/blood.2020009362. PMID: 33657221.
  • Mulroney, C.M., Bilal Abid, M., Bashey, A., Chemaly, R.F., Ciurea, S.O., Chen, M., Dandoy, C.E., Diaz Perez, M.A., Friend, B.D., Fuchs, E., Ganguly, S., Goldsmith, S.R., Kanakry, C.G., Kim, S., Komanduri, K.V., Krem, M.M., Lazarus, H.M., Ljungman, P., Maziarz, R., Nishihori, T., Patel, S.S., Perales, M.A., Romee, R., Singh, A.K., Reid Wingard, J., Yared, J., Riches, M., & Taplitz, R. Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Br J Haematol. 2021 Jul;194(1):145-157. doi: 10.1111/bjh.17563. Epub 2021 Jun 14. PMID: 34124796.
  • Liu, L., Fiala, M., Gao, F., King, J., Goldsmith, S., Wildes, T.M., Stockerl-Goldstein, K., Vij, R., & Schroeder, M.A. A single-center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. Leuk Lymphoma. 2021 Jun 18:1-4. doi: 10.1080/10428194.2021.1941940. Epub ahead of print. PMID: 34142630.

Invited Publications

  • Goldsmith, S.R., Lovell, A.R., & Schroeder, M.A. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy. Drugs Today. 2019, 55(9): 545
  • Moreau, P., Touzeau, C., Vij, R., Goldsmith, S.R., & Rosko, A.E. Newly Diagnosed Myeloma in 2020. American Society of Clinical Oncology Educational Book. 2020:40, 1-15
  • Goldsmith, S.R., Ghobadi, A., & DiPersio, J.F. Hematopoietic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors. Frontiers in Onc. 2020 Dec 22;10:608916. doi: 10.3389/fonc.2020.608916. eCollection 2020.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Recommend this provider office
5.0
Provider explain in way you understand
5.0
Provider listen carefully to you
5.0
Know important info medical history
5.0
Show respect for what you say
5.0
Spend enough time with you
4.9
Rate provider 0-10
03/20/26
I received care from 4 different providers before [...] attending COH. You have no equals. You are all remarkable. Even the shuttle drivers are courteous and nice! - Verified patient
02/18/26
[...] Dr. Goldsmith is extraordinary. I have already referred one other newly diagnosed myeloma patient to him (who is also very happy with him). CITY OF HOPE IS FORTUNATE TO HAVE HIM ON THE CLINICAL TEAM. Moreover, my experience with Dr. Goldsmith and with City of Hope in general led me to refer two other people close to me [...] - Verified patient
02/08/26
Dr. Goldsmith is caring and listens to me (the patient) wrt my concerns. I feel he is doing and prescribing things with my best interest in mind. I have confidence in Dr. Goldsmith. - Verified patient
02/07/26
I would recommend Dr. Goldsmith to anyone who has myeloma. [...] - Verified patient
02/07/26
Dr. Goldsmith was excellent. He explained everything so we clearly understood it. He answered all questions. He encouraged our input, developing a treatment plan - Verified patient